Ambenium parenteral: from regulatory approval to clinical practice

Dmitry S. Kurilchenko , Maya A. Kazakova , Yulia G. Kupryashkina , Maria V. Feoktistova , Sergey M. Kryzhanovsky , Elena I. Chukanova

For citation:

Abstract

Aims. To assess the clinical rationale for the use of Ambenium® Parenteral in acute pain, primarily in patients with low back pain, based on data from clinical trials and real-world clinical practice.

Methods. A review of publications on the pharmacological properties of phenylbutazone and the study results for Ambenium® Parenteral, containing phenylbutazone and lidocaine, was conducted. Data from a randomized comparative clinical trial in patients with acute low back pain, as well as findings from real-world clinical practice studies in pain syndromes of various origins, were analyzed.

Results. Ambenium® Parenteral was shown to provide an earlier onset of analgesic effect, contribute to a marked reduction in pain intensity, and reduce the proportion of patients with an insufficient response to therapy. In real-world clinical practice studies, the drug demonstrated efficacy in back pain and osteoarthritic joint pain and a good tolerability with short-term use. Conclusion. Ambenium® Parenteral is a clinically justified option for the treatment of acute pain, combining proven efficacy, rapid onset of analgesic action, and an acceptable safety profile when used according to the approved indications and dosing regimen.

Keywords: ambenium, back pain, phenylbutazone, lidocaine.

References

1. Gibbs D, McGahan BG, Ropper AE, Xu DS. Back Pain: Differential Diagnosis and Management. Neurol Clin 2023;41(1):61-76. DOI: 10.1016/j.ncl.2022.07.002

2. Hoy D, Brooks P, Blyth F, Buchbinder R. The Epidemiology of low back pain. Best Pract Res Clin Rheumatol 2010;24(6):769-81.

3. Varrassi G, Hanna M, Macheras G et al. Multimodal analgesia in moderate-to-severe pain: a role for a new fixed combination of dexketoprofen and tramadol. Curr Med Res Opin 2017;33:1165-73. DOI: 10.1080/03007995.2017.1310092

4. Elwyn G, Frosch DL, Kobrin S. Implementing shared decision-making: consider all the consequences. Implement Sci 2016;(11):114. DOI: 10.1186/s13012-016-0480-9

5. Phillips WJ, Currier BL. Analgesic pharmacology: II. Specific analgesics. J Am Acad Orthop Surg 2004;12(4):221-33.

6. Shekelle PG, Newberry SJ, FitzGerald JD et al. Management of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline. Ann Intern Med 2017;166(1):37-51.

7. Свинцицкая И.С., Волков К.Ю., Бологов С.Г. Фенилбутазон: место неселективных НПВП в современной врачебной практике. РМЖ. 2021; 29(7):62-5.

Svintsitskaya I.S., Volkov K.Yu., Bologov S.G. Phenylbutazone: the place of non-selective NSAIDs in modern medical practice. RMJ. 2021; 29(7):62-5. (in Russian).

8. Chaiamnuay S, Allison JJ, Curtis JR. Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs. Am J Health Syst Pharm. 2006;63(19):1837-51.

9. Журавлева М.В. и др. Рациональное применение НПВП – баланс эффективности и безопасности (обзор литературы). Международный журнал прикладных и фундаментальных исследований. 2016;(6-4):687-96.

Zhuravleva M.V. et al. Rational use of NSAIDs is a balance of efficacy and safety (literature review). International Journal of Applied and Fundamental Research. 2016;(6-4):687-96 (in Russian).

10. Worboys M, Toon E. Phenylbutazone (Bute, PBZ, EPZ): one drug across two species. Hist Philos Life Sci 2018;40(2):27.

11. Василюк В.Б., Сыраева Г.И., Фарапонова М.Ф. Обзор эффективности и безопасности нестероидных противовоспалительных препаратов для лечения острого приступа подагрического артрита. РМЖ. Медицинское обозрение. 2021;5(2):96-101. DOI: 10.32364/2587-6821-2021-5-2-96-101

Vasilyuk V.B., Syraeva G.I., Faraponova M.V. Efficacy and safety of non-steroidal anti-inflammatory drugs for acute attack of gout. Russian Medical Inquiry. 2021;5(2):96-101. DOI: 10.32364/2587-6821-2021-5-2-96-101 (in Russian).

12. EMA. Joint Statement of EMA and EFSA on the presence of residues of phenylbutazone in horse meat. EFSA Journal 2013; 11(4):51.

13. Lees P, Toutain P-L. Pharmacokinetics, pharmacodynamics, metabolism, toxicology and residues of phenylbutazone in humans and horses. Vet J 2013;196(3):294-303.

14. Aarbakke J. Clinical pharmacokinetics of phenylbutazone. Clin Pharmacokinet 1978;3(5):369-380.

15. Bird HA et al. A phenylbutazone dose-finding study in rheumatoid arthritis. Eur J Clin Pharmacol 1983; 24(6):773-6.

16. Mena HR, Willkens RF. Treatment of ankylosing spondylitis with flurbiprofen or phenylbutazone. Eur J Clin Pharmacol 1977;11(4):263-6.

17. Franssen MJ, Gribnau FW, van de Putte LB. A comparison of diflunisal and phenylbutazone in the treatment of ankylosing spondylitis. Clin Rheumatol 1986;5(2):210-20.

18. Chalem F et al. Diftalone: a new non-steroidal anti-inflammatory agent: comparative study with phenylbutazone in the treatment of rheumatoid arthritis. J Int Med Res 1977;5(1):18-25.

19. Orme M et al. Plasma concentration of phenylbutazone and its therapeutic effect-studies in patients with rheumatoid arthritis. Br J Clin Pharmacol 1976;3(1):185-191.

20. López Sánchez J, Yañez Marchena G. Meclofenamate sodium, phenylbutazone, and naproxen in the treatment of degenerative joint disease. Report of a placebo-controlled double-blind clinical comparison. Arzneimittelforschung 1983;33(4):653-6.

21. Лукьянчук Е. Выбор нестероидных противовоспалительных препаратов для купирования острой боли при ревматических заболеваниях. Український ревматологічний журнал. 2015;(2):29-30.

Lukyanchuk E. The choice of nonsteroidal anti-inflammatory drugs for relief of acute pain in rheumatic diseases. Ukrainian Rheumatology Journal. 2015;(2):29-30 (in Russian).

22. Baron R, Mick G, Serpell M. The relevance of real-world data for the evaluation of neuropathic pain treatments. Pain Management 2022;12(7):845-57. DOI: 10.2217/pmt-2022-0057

23. Thieffry S, Klein P, Baulac M et al. Understanding the challenge of comparative effectiveness research in focal epilepsy: A review of network meta‐analyses and real‐world evidence on antiepileptic drugs. Epilepsia 2020;61(4):595-609. DOI: 10.1111/epi.16476

24. Пешехонова Л.К., Пешехонов Д.В. Эффективность коррекции острого болевого синдрома у больных остеоартритом с коморбидной патологией в клинике внутренних болезней. Системный анализ и управление в биомедицинских системах. 2021;20(3):23-32.

Peshekhonova L.K., Peshekhonov D.V. Effectiveness of correction of acute pain syndrome in patients with osteoarthritis with comorbid pathology in the clinic of internal diseases. Systems analysis and management in biomedical systems. 2021;20(3):23-32 (in Russian).

25. Василюк В.Б., Фарапонова М.В., Сыраева Г.И. Выбор НПВП для лечения острой и хронической боли у пациентов с ревматоидным артритом на амбулаторно-поликлиническом этапе. РМЖ. 2020;28(12)30-4.

Vasilyuk V.B., Faraponova M.V., Syraeva G.I. Selection of NSAIDs for the treatment of acute and chronic pain in patients with rheumatoid arthritis at the outpatient stage. RMJ. 2020;28(12):30-4. (in Russian).

26. Нестеренко В.А., Каратеев А.Е., Зеленов В.А., Зоткин Е.Г. Эффективность и безопасность использования фенилбутазона для внутримышечного введения при остеоартрите коленного сустава. РМЖ. 2021;29(6):63-6.

Nesterenko V.A., Karateev A.E., Zelenov V.A., Zotkin E.G. Efficacy and safety of phenylbutazone use intramuscularly in knee osteoarthritis. RMJ. 2021; 29(6):63-6 (in Russian).

27. Курильченко Д.С., Казакова М.А., Купряшкина Ю.Г. и др. Боль в спине. Результаты неинтервенционного исследования применения препарата Амбениум® парентерал в условиях реальной клинической практики. Клинический разбор в общей медицине. 2024;5(5):21-6. DOI: 10.47407/kr2024.5.5.00401

Kurilchenko D.S., Kazakova M.A., Kupryashkina Yu.G. et al. Back pain. Results of a non-interventional study of using Ambenium® parenteral in routine clinical practice. Clinical review for general practice. 2024;5(5):21-6 (In Russ.). DOI: 10.47407/kr2024.5.5.00401 (in Russian).

28. Курильченко Д.С., Казакова М.А., Купряшкина Ю.Г., Феоктистова М.В., Крыжановский С.М., Чуканова Е.И. Нарушение жизнедеятельности у пациентов с болью в спине. Клинический разбор в общей медицине. 2025;6(4):28-32. DOI: 10.47407/kr2025.6.4.00591

Kurilchenko D.S., Kazakova M.A., Kupryashkina Yu.G. et al. Impaired functioning in patients with back pain. Clinical review for general practice. 2025;6(4):28-32. DOI: 10.47407/kr2025.6.4.00591 (in Russian).

For citation:Kurilchenko D.S., Kazakova M.A., Kupryashkina Yu.G., Feoktistova M.V., Kryzhanovsky S.M., Chukanova E.I. Ambenium parenteral: from regulatory approval to clinical practice. Clinical review for general practice. 2026; 7 (3): 48–52 (In Russ.). DOI: 10.47407/kr2026.7.3.00793

All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Clinical review for general practice